title: Modelling HIV-1 2-LTR dynamics following raltegravir intensification.
abstract: A model of reservoir activation and viral replication is introduced accounting for the production of 2-LTR HIV-1 DNA circles following antiviral intensification with the HIV integrase inhibitor raltegravir, considering contributions of de novo infection events and exogenous sources of infected cells, including quiescent infected cell activation. The model shows that a monotonic increase in measured 2-LTR concentration post intensification is consistent with limited de novo infection primarily maintained by sources of infected cells unaffected by raltegravir, such as quiescent cell activation, while a transient increase in measured 2-LTR concentration is consistent with significant levels of efficient (R0 > 1) de novo infection. The model is validated against patient data from the INTEGRAL study and is shown to have a statistically significant fit relative to the null hypothesis of random measurement variation about a mean. We obtain estimates and confidence intervals for the model parameters, including 2-LTR half-life. Seven of the 13 patients with detectable 2-LTR concentrations from the INTEGRAL study have measured 2-LTR dynamics consistent with significant levels of efficient replication of the virus prior to treatment intensification.
authors: Department of Electrical and Computer Engineering, University of Delaware, Newark, DE, USA.
authors: Rutao
authors: R
authors: Luo
authors: E Fabian
authors: EF
authors: Cardozo
authors: Michael J
authors: MJ
authors: Piovoso
authors: Hulin
authors: H
authors: Wu
authors: Maria J
authors: MJ
authors: Buzon
authors: Javier
authors: J
authors: Martinez-Picado
authors: Ryan
authors: R
authors: Zurakowski
mesh_terms: D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D004270:DNA, Circular / Q000378:metabolism*; D004279:DNA, Viral / Q000378:metabolism*; D004197:Disease Reservoirs / Q000821:virology; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000235:genetics*; D006801:Humans; D008954:Models, Biological; D011760:Pyrrolidinones / Q000008:administration & dosage / Q000494:pharmacology*; D000068898:Raltegravir Potassium; D013997:Time Factors; D014779:Virus Replication / Q000187:drug effects*
chemical_list: D004270:DNA, Circular; D004279:DNA, Viral; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium
keywords: HIV; cryptic viremia; mathematical biology
references: Clin Biochem Rev. 2008 Aug;29 Suppl 1:S49-52
references: 18852857
references: AIDS. 2007 Nov 12;21(17):2315-21
references: 18090280
references: AIDS. 2000 Jul 7;14(10):1357-63
references: 10930150
references: AIDS. 2003 Mar 28;17(5):679-83
references: 12646790
references: Bull Math Biol. 2008 Apr;70(3):785-99
references: 18247096
references: Virology. 1994 Dec;205(2):470-8
references: 7975248
references: Curr Opin HIV AIDS. 2010 Nov;5(6):491-7
references: 20978392
references: Nat Med. 2010 Apr;16(4):460-5
references: 20228817
references: Curr Opin HIV AIDS. 2011 Jan;6(1):49-56
references: 21228755
references: BMC Mol Biol. 2008 Jul 17;9:63
references: 18631407
references: AIDS. 2004 May 21;18(8):1147-58
references: 15166530
references: Biom J. 2010 Aug;52(4):470-86
references: 20661953
references: PLoS Pathog. 2012 Feb;8(2):e1002506
references: 22319447
references: Science. 1997 Nov 14;278(5341):1291-5
references: 9360926
references: PLoS Pathog. 2011 Oct;7(10):e1002314
references: 22046128
references: Stat Med. 2002 Aug 15;21(15):2199-214
references: 12210633
references: J Virol. 2005 Aug;79(15):9625-34
references: 16014925
references: AIDS. 2003 Mar 28;17(5):749-50
references: 12646799
references: Science. 2010 Jul 9;329(5988):174-80
references: 20616270
references: Stat Methods Med Res. 2005 Apr;14(2):171-92
references: 15807150
references: J Virol. 2006 Jul;80(13):6441-57
references: 16775332
references: AIDS. 2010 Oct 23;24(16):2451-60
references: 20827162
references: Antivir Ther. 2012;17(2):355-64
references: 22290239
references: J Infect Dis. 2004 Apr 15;189(8):1452-65
references: 15073683
references: J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):229-35
references: 22083073
references: Curr Opin Infect Dis. 2010 Dec;23(6):628-32
references: 20847693
references: J Virol. 1997 Mar;71(3):2059-71
references: 9032338
references: J Clin Microbiol. 2003 Oct;41(10):4531-6
references: 14532178
references: J Virol. 2002 Apr;76(8):3739-47
references: 11907213
references: Biometrics. 2009 Mar;65(1):292-300
references: 18510656
references: Virol J. 2010 Dec 03;7:354
references: 21129188
references: Clin Infect Dis. 2012 Feb 1;54(3):451-3
references: 22016501
references: J Clin Microbiol. 2006 Dec;44(12):4371-5
references: 17005750
references: JAMA. 1999 Nov 3;282(17):1627-32
references: 10553788
references: PLoS One. 2012;7(7):e40198
references: 22815727
references: AIDS. 2010 Oct 23;24(16):2535-9
references: 20651585
references: PLoS Pathog. 2007 Apr;3(4):e46
references: 17411338
references: J Clin Microbiol. 2012 Oct;50(10):3381-2
references: 22837324
references: Math Biosci. 1993 Mar;114(1):81-125
references: 8096155
references: Science. 2011 Dec 23;334(6063):1614
references: 22194536
references: Antiviral Res. 1999 Feb;41(1):45-56
references: 10321578
references: Nat Med. 2000 Jul;6(7):757-61
references: 10888923
references: J Virol. 1996 May;70(5):3098-107
references: 8627789
references: Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15109-14
references: 10611346
references: JAMA. 2001 Jul 11;286(2):196-207
references: 11448283
references: SIAM Rev Soc Ind Appl Math. 2011 Jan 1;53(1):3-39
references: 21785515
references: J Virol. 2011 May;85(10):5220-3
references: 21367910
references: JAMA. 2005 Feb 16;293(7):817-29
references: 15713771
references: J Virol. 2002 Apr;76(8):4138-44
references: 11907256
references: PLoS Pathog. 2011 Feb;7(2):e1001303
references: 21383975
references: J Antimicrob Chemother. 2010 Mar;65(3):434-7
references: 20051476
references: J Virol. 2003 Apr;77(8):5037-8
references: 12663814
references: Antivir Ther. 2009;14(2):263-71
references: 19430101
references: Nat Med. 2000 Jan;6(1):76-81
references: 10613828
references: Nature. 1999 Oct 28;401(6756):874-5
references: 10553903
references: Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9403-8
references: 19470482
references: J Virol. 2004 Jan;78(2):968-79
references: 14694128
references: PLoS One. 2011;6(6):e21081
references: 21687638
references: Clin Infect Dis. 2010 Mar 15;50(6):912-9
references: 20156060
references: Antivir Chem Chemother. 2009;19(4):157-64
references: 19374143
references: Bull Math Biol. 2006 Nov;68(8):2005-25
references: 16900456
references: Genes Nutr. 2009 Jun;4(2):95-102
references: 19408033
references: Math Biosci Eng. 2009 Apr;6(2):261-82
references: 19364152